FDA Approves Zytiga In Earlier Prostate Cancer Setting
This article was originally published in The Pink Sheet Daily
FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.
You may also be interested in...
Valeant To Buy Dendreon’s Never-Was Cancer Vaccine Provenge
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.
Patient-Reported Outcomes in Oncology: The Jakafi and Zytiga Exceptions
Oncology is the biggest area of biopharmaceutical R&D where patient-reported outcomes are not routinely collected during clinical trials. There are some good reasons why. Jakafi and Zytiga remain outliers oncology treatment with a PRO in the approved label.
No Happy Endings For Dendreon As It Closes Another Chapter
The once-hot biotech finally has filed for bankruptcy as it does its best to pay back note holders and looks to sell its floundering prostate cancer therapy in an effort to honor remaining employee contracts.